Advaxis (NASDAQ: ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Princeton, US
Size (employees)
90 (est)
Advaxis was founded in 2002 and is headquartered in Princeton, US

Key People at Advaxis

Anthony Lombardo

Anthony Lombardo

Interim CEO
Thomas J. McKearn

Thomas J. McKearn

Roni A. Appel

Roni A. Appel

Richard Berman

Richard Berman

Robert G. Petit

Robert G. Petit

Executive Vice President and Chief Scientific Officer

Advaxis Office Locations

Advaxis has an office in Princeton
Princeton, US (HQ)
305 College Rd E

Advaxis Data and Metrics

Advaxis Financial Metrics

Advaxis's revenue was reported to be $4 m in FY, 2016

Revenue (FY, 2016)

4 m

Net income (FY, 2016)

(73.6 m)

EBIT (FY, 2016)

(76.5 m)

Market capitalization (20-Jul-2017)

288.5 m

Closing share price (20-Jul-2017)


Cash (31-Oct-2016)

112.8 m
Advaxis's current market capitalization is $288.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


1.9 m1 m4 m

Revenue growth, %


R&D expense

48.8 m

General and administrative expense

31.7 m

Operating expense total

71.4 m20.5 m48.7 m80.5 m


(69.5 m)(19.5 m)(48.7 m)(76.5 m)

EBIT margin, %


Interest expense

987.7 k5.3 k

Interest income

331.5 k

Income tax expense

725.2 k2.4 m2.5 m

Net Income

(67.5 m)(16.5 m)(47 m)(73.6 m)
USDFY, 2013FY, 2014FY, 2016


20.6 m17.6 m112.8 m

Accounts Receivable

80.1 k

Current Assets

20.8 m20.5 m159.9 m

Total Assets

23.6 m23.4 m169 m

Accounts Payable

3.8 m1.4 m1.7 m

Current Liabilities

4.9 m2.7 m27.7 m

Total Liabilities

49.7 m

Additional Paid-in Capital

88.5 m107.6 m327.1 m

Retained Earnings

(87 m)(207.7 m)

Total Equity

20.6 m119.3 m

Financial Leverage

1.1 x1.4 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(20 m)(16.5 m)(73.6 m)

Depreciation and Amortization

19.3 k27.6 k283.5 k

Accounts Receivable

65.2 k

Accounts Payable

(1.9 m)8.4 m

Cash From Operating Activities

(8.7 m)(17 m)49 m(9.1 m)

Purchases of PP&E

(24.6 k)(24.6 k)(3.2 m)

Cash From Investing Activities

(295.7 k)(439.7 k)1.6 m

Short-term Borrowings

(690.8 k)

Cash From Financing Activities

29.6 m14.5 m53.7 m

Interest Paid

103.4 k

Income Taxes Paid

50 k
USDY, 2016


83.2 k

Financial Leverage

1.4 x

Advaxis Market Value History

Advaxis Online and Social Media Presence

Advaxis Company Life and Culture

You may also be interested in